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Clinical Efficacy and Safety of a Combined Loratadine-
Betamethasone Oral Solution in the Treatment of Severe
Pediatric Perennial Allergic Rhinitis
Teolinda Mendoza de Morales, MD1 and Francis Sa´nchez, MD2
Background: Allergic rhinitis is a highly prevalent condition, par-
ticularly among children, whose schoolwork and quality of life may
be impaired by its symptoms.
Methods: In this prospective, multicenter study, children between 6
and 12 years old with a diagnosis of severe perennial allergic rhinitis
received a combination of the nonsedating antihistamine loratadine
and the corticosteroid betamethasone in an oral solution for 5 days.
Results: The total nasal and ocular symptom score was significantly
reduced from 11.4 (2.1) before treatment to 2.9 (2.4) after
treatment (P  0.01). Significant reductions (P  0.01) were also
observed for sneezing, nasal pruritus, nasal congestion, rhinorrhea,
postnasal drip, and ocular erythema and pruritus. No adverse events
were reported, and no subject discontinued treatment.
Conclusions: The combination of loratadine and betamethasone in
an oral solution was safe and effective as initial short-term treatment
for symptoms of severe perennial allergic rhinitis in school-aged
children.
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allergic rhinitis, quality of life
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Allergic rhinitis (AR) is a widespread health problem inVenezuela, with a reported prevalence as high as 39%.1,2
Approximately 40% of children and adolescents have AR,
although the actual figures may be higher because AR is
frequently unrecognized and consequently left untreated.3
The incidence of AR in children increases with age: Up to
14.9% of 6- and 7-year-old children and as high as 39.7% of
13- and 14-year-old children are affected by AR.4 The risk of
developing AR increases by a factor of 2 if a child has 1
atopic parent and by a factor of 4 if both parents are atopic.5
Allergic rhinitis tends to be more common in boys than in
girls up to the age of 15 years, after which the gender
disparity usually ends.6
School performance and quality of life (QoL) of chil-
dren with AR are generally worse than those of children
without the disorder. Children with AR tend to be more
irritable and tired than those without AR and can therefore be
inattentive and disruptive in the classroom.4 In the United
States, children are absent for more than 2 million school
days annually because of AR. A study of adolescents (N 
1834) in the United Kingdom found that subjects with AR
were 40% more likely than those in the control group to drop
a grade in English, science, or math in their critically impor-
tant final General Certificate of Secondary Education exam-
inations, which are administered in the spring when AR
symptoms occur, different from practice exams taken in the
winter when symptoms were not present.7 Allergic children
are also prone to psychological problems such as low self-
esteem, shyness, depression, anxiety, and fearfulness.8–10
Perennial AR (PAR) is a year-round condition that is
generally caused by indoor allergens such as dust mites,
mold, cat dander, and cockroach allergens.11,12 A study of
adolescents and adults in the United Kingdom found that
56% of those with AR and 8% of the general population
experienced PAR.6 Perennial AR is associated with at least
two of the following symptoms: nasal congestion, sneez-
ing, and serous or seromucus hypersecretion. Congestion
and mucus production (postnasal drip) predominate in
most patients with PAR; sneezing, nasal pruritus, and
aqueous rhinorrhea may be minimal.13 Many patients with
PAR may also be bothered by ocular (itchy, red, or watery
eyes) or other non-nasal symptoms, such as headache,
thirst, and poor concentration.8,14
Two widely accepted guidelines recommend the use of
a second-generation, nonsedating H1 antihistamine in combi-
nation with an intranasal corticosteroid (INS) for the treat-
ment of PAR. Guidelines developed by the Allergic Rhinitis
and Its Impact on Asthma Workshop recommend this com-
bination as first-line therapy for PAR when congestion is the
predominant symptom.15 The European Academy of Aller-
gology and Clinical Immunology guidelines recommend this
combination in children with PAR when neither treatment as
monotherapy sufficiently controls symptoms.16
The nonsedating antihistamine loratadine is a selective
H1-receptor antagonist with a 24-hour duration of effect and
a favorable adverse event (AE) profile.11 In two double-blind,
placebo-controlled, randomized clinical studies with adults
and adolescents, loratadine reduced both the nasal and ocular
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symptoms of PAR and was well-tolerated.17,18 Loratadine has
also been found to reduce nasal and ocular symptoms in
children with AR19,20 and to be safe in children as young as
2 years old.21 The corticosteroid betamethasone has effec-
tively controlled the nasal symptoms of PAR in a study
extending over 28 days. Given its risk for systemic AEs
during prolonged treatment, betamethasone is generally used
as a short-term treatment for patients with PAR whose symp-
toms do not respond to other medications.22,23
This study evaluated the safety and efficacy of an oral
solution (1 mg/0.05 mg/1 mL) combining loratadine and
betamethasone at doses of 10 mg and 0.5 mg, respectively, as
initial, short-term treatment for school-aged children with
severe PAR in Venezuela. Severe PAR was defined in this
study as PAR that alters nasal airflow, interferes with daily
activities, and affects QoL, learning, and sleep. This is the
first study of an oral solution of these two agents for the
treatment of PAR.
METHODS
This open-label, prospective, multicenter, single-group
clinical trial enrolled pediatric subjects presenting to otorhi-
nolaryngology offices of participating clinics for symptoms
related to AR. To be included, subjects had to be aged 6 to 12
years and in good general health, with no other relevant
clinical conditions. They must also have had a clinical
diagnosis of PAR, with the presence of 3 or more of the
following symptoms: sneezing, nasal pruritus, nasal con-
gestion, rhinorrhea, postnasal drip, and ocular erythema or
pruritus. Perennial AR was confirmed in approximately
40% of subjects with a positive skin prick test reaction or
a radioallergosorbent test that was class 2 or higher to
house dust mites or cat dander. Further, endoscopy of the
upper airways was performed.
The diagnosis of PAR was based on Allergic Rhinitis
and Its Impact on Asthma Workshop criteria for moderate
to severe persistent AR (symptoms present 4 days/wk
and 4 weeks/y, with one or more of the following
characteristics: troublesome symptoms, sleep disturbance,
impairment of daily activities/sports, and reduced produc-
tivity in school). Total symptom score for study admission
was 8 or more (each symptom scored from 0 [none] to 3
[severe] with a total possible score of 15). Approximately
80% of the subjects reported PAR for 1 year with
symptoms present 5 days/wk.
Subjects were excluded if they had coexisting chronic
conditions (except for asthma, atopic dermatitis, and sinus-
itis), presence of systemic fungal infection, or cognitive or
behavioral disturbance, if they were currently receiving oral
or parenteral steroid treatment or concomitant phenobarbital,
rifampicin, phenytoin (diphenylhydantoin), or ephedrine, or
if they had known hypersensitivity to either loratadine or
betamethasone.
The study was conducted according to Good Clinical
Practices and was approved by each center’s ethics commit-
tee. School-aged children who met the inclusion criteria and
whose parents signed informed consent forms were admitted
to the study (day 0). On days 1 to 5, participants received 10
mL of a loratadine (1 mg/mL)/betamethasone (0.05 mg/mL)
oral solution once daily at approximately 8:00 AM. Children
were evaluated on days 0 and 6. Individual and total symptom
scores (main efficacy parameters) were registered at both
visits. Tolerability was assessed by AE reports. No additional
medications for the symptoms of AR were permitted during
the study.
Data Analysis
The primary efficacy end point was reduction from
baseline in total nasal and ocular symptoms, and individual
symptoms (sneezing or nasal pruritus, nasal congestion, rhi-
norrhea, postnasal drip, or ocular erythema or pruritus).
Symptoms were rated on a 4-point scale for severity (0 
none; AEs3  severe) and frequency (0  none; 3  5
days/wk). Clinical response was evaluated by comparing
symptom scores on day 0 and day 6 using the Student t test.
Each subject served as his or her own control (analysis of
difference before and after treatment).
RESULTS
A total of 100 subjects (69 boys) with a mean age of
9.73 (1.77) years were enrolled and included in the analysis
(Table 1). Seventy-nine subjects cited pathologic evidence
demonstrating that sinusitis (53%) or asthma (44%) was also
present. Subjects’ additional disorders are listed in Table 2.
Two patients refused to participate in the study due to
concerns about possible AEs; their results were not included.
Efficacy
The mean total symptom score (nasal and ocular symp-
toms) decreased from 11.4  2.1 points at baseline to 2.9 
2.4 points after 5 days of treatment with the loratadine-
betamethasone oral solution (P  0.01) (Fig. 1). Significant
decreases (P  0.01) from baseline were also reported for
each individual symptom (sneezing, nasal pruritus, nasal
congestion, rhinorrhea, postnasal drip, and ocular erythema
or pruritus), as shown in Figure 2. The greatest improvements
in individual symptoms were seen with nasal congestion,
with a difference of 1.92 points between the loratadine-
betamethasone solution and placebo groups, and with sneez-
ing, with a difference of 1.86 points.
Adherence
Subjects were instructed to return their medication
bottles to the investigators at the completion of the study. All
TABLE 1. Subject Distribution by Age
Age (yr) Frequency (n) % Accumulated %
6 5 5.0 5.0
7 5 5.0 10.0
8 21 21.0 31.0
9 10 10.0 41.0
10 18 18.0 59.0
11 22 22.0 81.0
12 19 19.0 100.0
Total 100 100.0 —
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participants reported complete adherence to the treatment
regimen.
Safety and Tolerability
No AEs were reported for any subject, and nobody
withdrew from the study.
DISCUSSION
Allergic rhinitis is a common disease that can be
extremely bothersome and, if not treated properly, can lead
to significant comorbidities and impairment of patients’
daily activities.4,24 Children can be especially vulnerable to
the deleterious effects of AR. Children with AR are prone
to comorbid conditions such as asthma, rhinosinusitis,
otitis media, and nasal polyposis.4 They can also fall
behind in their schoolwork, become isolated from their
classmates, and experience psychological disorders such as
depression and anxiety.7–10,25
The rationale for combining an antihistamine with a
corticosteroid is based on each drugs’ mechanism of action in
both the early and the late phases of allergic reaction. Anti-
histamines inhibit the release of H1 histamine from basophils
and mast cells, which alleviates symptoms of sneezing, itch-
ing, and rhinorrhea.11,18,26 By contrast, corticosteroids miti-
gate nasal blockage (a hallmark of congestion) induced by the
chronic inflammatory process and a variety of mediators,
which only partially respond to H1 antihistamines.11,23,27
The loratadine-betamethasone oral solution evaluated
in this study has the potential to control symptoms in both
phases of the allergic reaction. Loratadine exerts an antihis-
taminic effect that is characterized by attenuation of symp-
toms resulting from histamine release in the nasal mucosa
during the early-phase allergic reaction. Betamethasone has
an anti-inflammatory effect, as suggested by the relief of
nasal congestion during the late-phase reaction. These results
demonstrate that this combination therapy in a liquid formu-
lation provides rapid and continuing relief of nasal and
non-nasal symptoms.
The results of this study corroborate those of a previous
clinical trial in which loratadine and betamethasone were
administered as joint therapy for AR. In this double-blind,
parallel-group study in subjects (N  299) with severe AR
and clinically significant obstruction, loratadine and beta-
methasone were used in combination and individually. The
combination was significantly more effective in controlling
symptoms, including nasal obstruction, than either drug ad-
ministered as monotherapy. Further, loratadine, administered
with betamethasone, resulted in a significant reduction in the
rate of relapse compared with the other treatment regimens.28
Studies in which loratadine was combined with an INS
have demonstrated similar results. Subjects receiving com-
bined adjunctive treatment with loratadine and the INSs
mometasone furoate and fluticasone propionate showed sig-
nificant improvements compared with those receiving pla-
cebo in nasal symptoms of AR and QoL.29,30
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FIGURE 1. Total PAR symptom scores before (at baseline) and after 5 days of treatment with loratadine-betamethasone oral
solution.
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An oral formulation, such as the one used in this study,
may enhance patient compliance because many children find
it difficult to swallow a tablet or use a nasal spray. Two
clinical studies of a syrup formulation of loratadine given at
doses of 5 mg and 10 mg to children as young as 3 years old
found that loratadine reduced both nasal and non-nasal symp-
toms of seasonal AR and PAR and was well-tolerated.31,32
Betamethasone was used in the solution at a relatively
low dose of 0.5 mg. This is the same dosage used in the
loratadine-betamethasone adjunctive treatment study cited
above,28 which was designed to be a study of low-dose
betamethasone. As with other first-generation corticosteroids
(eg, hydrocortisone, prednisolone, and dexamethasone), be-
tamethasone has been associated with systemic AEs.23 The
use of a lower dose may have contributed to the insignificant
AE profile of the loratadine-betamethasone solution. The
absence of any AEs in this study also suggests that the
solution may be well-tolerated during the repeated short
courses needed in the treatment of children with severe PAR.
The interpretation of the results of this study is limited
because it was not placebo-controlled; instead, comparison of
results was made pre- and posttreatment, with each subject
acting as his or her own control. Comparisons of pre- and
posttreatment efficacy variables have been utilized in other
studies which assessed the clinical impact of corticosteroids
in adults and children with AR.33,34 However, it is possible
that, over the course of this study, subjects’ symptoms may
have abated independent of loratadine/betamethasone treat-
ment as a result of regression to the mean.
Combination loratadine-betamethasone in an oral solu-
tion (1 mg/0.05 mg/1 mL) was a safe, well-tolerated, and
effective initial, short-term treatment for severe PAR in
children between 6 and 12 years old. No AEs were reported
for any subject, and nobody withdrew from the study; thus,
this formulation may be an appropriate option for short-term
control of the symptoms of PAR. Additional investigation of
this combination is required to determine its safety profile
when used for repeated exacerbations of PAR.
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